APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Oral Thrombopoietin Receptor Agonists

Compare research editions
View pricing & licenses

Selected research

Industry Research

Oral Thrombopoietin Receptor Agonists Industry Research Report 2026

Report ID 174020210528 December 2025134 pages

Choose your research edition.

Industry ResearchOral Thrombopoietin Receptor Agonists Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Oral Thrombopoietin Receptor Agonists Industry Growth and Trends Forecast to 2032119 pages · $3,450 USDMarket StructureGlobal Oral Thrombopoietin Receptor Agonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oral Thrombopoietin Receptor Agonists Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Oral Thrombopoietin Receptor Agonists Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Oral Thrombopoietin Receptor Agonists market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Oral Thrombopoietin Receptor Agonists is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Oral Thrombopoietin Receptor Agonists is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Oral Thrombopoietin Receptor Agonists is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Oral Thrombopoietin Receptor Agonists include Chia Tai Tianqing Pharmaceutical, Grand Pharmaceutical, Sichuan Kelun Pharmaceutical, 3SBio, Qilu Pharmaceutical, Jiangsu Hengrui Pharmaceuticals, Shanghai Fosun Pharmaceutical, Teva and Shionogi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Oral Thrombopoietin Receptor Agonists market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Oral Thrombopoietin Receptor Agonists Market by Company

Chia Tai Tianqing Pharmaceutical

Grand Pharmaceutical

Sichuan Kelun Pharmaceutical

3SBio

Qilu Pharmaceutical

Jiangsu Hengrui Pharmaceuticals

Shanghai Fosun Pharmaceutical

Teva

Shionogi

Novartis

Hetero

Annora Pharma

Amneal Pharmaceuticals

AkaRx

Actavis Laboratories

Oral Thrombopoietin Receptor Agonists Segment by Type

Avatrombopag

Eltrombopag

Herombopag

Lusutrombopag

Oral Thrombopoietin Receptor Agonists Segment by Application

Hospital and Clinic

Pharmacy

Other

Oral Thrombopoietin Receptor Agonists Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Thrombopoietin Receptor Agonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oral Thrombopoietin Receptor Agonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Thrombopoietin Receptor Agonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Oral Thrombopoietin Receptor Agonists manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Oral Thrombopoietin Receptor Agonists by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Oral Thrombopoietin Receptor Agonists in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Oral Thrombopoietin Receptor Agonists Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Oral Thrombopoietin Receptor Agonists Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Oral Thrombopoietin Receptor Agonists Sales Market Share by Manufacturers (2021-2026) Table 8. Global Oral Thrombopoietin Receptor Agonists Revenue of Manufacturers (2021-2026) Table 9. Global Oral Thrombopoietin Receptor Agonists Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Oral Thrombopoietin Receptor Agonists Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Oral Thrombopoietin Receptor Agonists Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Oral Thrombopoietin Receptor Agonists, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Oral Thrombopoietin Receptor Agonists, Product Type & Application Table 14. Global Oral Thrombopoietin Receptor Agonists Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Oral Thrombopoietin Receptor Agonists by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Chia Tai Tianqing Pharmaceutical Company Information Table 19. Chia Tai Tianqing Pharmaceutical Business Overview Table 20. Chia Tai Tianqing Pharmaceutical Oral Thrombopoietin Receptor Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Chia Tai Tianqing Pharmaceutical Oral Thrombopoietin Receptor Agonists Product Portfolio Table 22. Chia Tai Tianqing Pharmaceutical Recent Developments Table 23. Grand Pharmaceutical Company Information Table 24. Grand Pharmaceutical Business Overview Table 25. Grand Pharmaceutical Oral Thrombopoietin Receptor Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Grand Pharmaceutical Oral Thrombopoietin Receptor Agonists Product Portfolio Table 27. Grand Pharmaceutical Recent Developments Table 28. Sichuan Kelun Pharmaceutical Company Information Table 29. Sichuan Kelun Pharmaceutical Business Overview Table 30. Sichuan Kelun Pharmaceutical Oral Thrombopoietin Receptor Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Sichuan Kelun Pharmaceutical Oral Thrombopoietin Receptor Agonists Product Portfolio Table 32. Sichuan Kelun Pharmaceutical Recent Developments Table 33. 3SBio Company Information Table 34. 3SBio Business Overview Table 35. 3SBio Oral Thrombopoietin Receptor Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. 3SBio Oral Thrombopoietin Receptor Agonists Product Portfolio Table 37. 3SBio Recent Developments Table 38. Qilu Pharmaceutical Company Information Table 39. Qilu Pharmaceutical Business Overview Table 40. Qilu Pharmaceutical Oral Thrombopoietin Receptor Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Qilu Pharmaceutical Oral Thrombopoietin Receptor Agonists Product Portfolio Table 42. Qilu Pharmaceutical Recent Developments Table 43. Jiangsu Hengrui Pharmaceuticals Company Information Table 44. Jiangsu Hengrui Pharmaceuticals Business Overview Table 45. Jiangsu Hengrui Pharmaceuticals Oral Thrombopoietin Receptor Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Jiangsu Hengrui Pharmaceuticals Oral Thrombopoietin Receptor Agonists Product Portfolio Table 47. Jiangsu Hengrui Pharmaceuticals Recent Developments Table 48. Shanghai Fosun Pharmaceutical Company Information Table 49. Shanghai Fosun Pharmaceutical Business Overview Table 50. Shanghai Fosun Pharmaceutical Oral Thrombopoietin Receptor Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Shanghai Fosun Pharmaceutical Oral Thrombopoietin Receptor Agonists Product Portfolio Table 52. Shanghai Fosun Pharmaceutical Recent Developments Table 53. Teva Company Information Table 54. Teva Business Overview Table 55. Teva Oral Thrombopoietin Receptor Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Teva Oral Thrombopoietin Receptor Agonists Product Portfolio Table 57. Teva Recent Developments Table 58. Shionogi Company Information Table 59. Shionogi Business Overview Table 60. Shionogi Oral Thrombopoietin Receptor Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Shionogi Oral Thrombopoietin Receptor Agonists Product Portfolio Table 62. Shionogi Recent Developments Table 63. Novartis Company Information Table 64. Novartis Business Overview Table 65. Novartis Oral Thrombopoietin Receptor Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Novartis Oral Thrombopoietin Receptor Agonists Product Portfolio Table 67. Novartis Recent Developments Table 68. Hetero Company Information Table 69. Hetero Business Overview Table 70. Hetero Oral Thrombopoietin Receptor Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Hetero Oral Thrombopoietin Receptor Agonists Product Portfolio Table 72. Hetero Recent Developments Table 73. Annora Pharma Company Information Table 74. Annora Pharma Business Overview Table 75. Annora Pharma Oral Thrombopoietin Receptor Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Annora Pharma Oral Thrombopoietin Receptor Agonists Product Portfolio Table 77. Annora Pharma Recent Developments Table 78. Amneal Pharmaceuticals Company Information Table 79. Amneal Pharmaceuticals Business Overview Table 80. Amneal Pharmaceuticals Oral Thrombopoietin Receptor Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Amneal Pharmaceuticals Oral Thrombopoietin Receptor Agonists Product Portfolio Table 82. Amneal Pharmaceuticals Recent Developments Table 83. AkaRx Company Information Table 84. AkaRx Business Overview Table 85. AkaRx Oral Thrombopoietin Receptor Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. AkaRx Oral Thrombopoietin Receptor Agonists Product Portfolio Table 87. AkaRx Recent Developments Table 88. Actavis Laboratories Company Information Table 89. Actavis Laboratories Business Overview Table 90. Actavis Laboratories Oral Thrombopoietin Receptor Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Actavis Laboratories Oral Thrombopoietin Receptor Agonists Product Portfolio Table 92. Actavis Laboratories Recent Developments Table 93. Global Oral Thrombopoietin Receptor Agonists Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 94. Global Oral Thrombopoietin Receptor Agonists Sales by Region (2021-2026) & (K Units) Table 95. Global Oral Thrombopoietin Receptor Agonists Sales Market Share by Region (2021-2026) Table 96. Global Oral Thrombopoietin Receptor Agonists Sales by Region (2027-2032) & (K Units) Table 97. Global Oral Thrombopoietin Receptor Agonists Sales Market Share by Region (2027-2032) Table 98. Global Oral Thrombopoietin Receptor Agonists Revenue by Region (2021-2026) & (US$ Million) Table 99. Global Oral Thrombopoietin Receptor Agonists Revenue Market Share by Region (2021-2026) Table 100. Global Oral Thrombopoietin Receptor Agonists Revenue by Region (2027-2032) & (US$ Million) Table 101. Global Oral Thrombopoietin Receptor Agonists Revenue Market Share by Region (2027-2032) Table 102. North America Oral Thrombopoietin Receptor Agonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. North America Oral Thrombopoietin Receptor Agonists Sales by Country (2021-2026) & (K Units) Table 104. North America Oral Thrombopoietin Receptor Agonists Sales by Country (2027-2032) & (K Units) Table 105. North America Oral Thrombopoietin Receptor Agonists Revenue by Country (2021-2026) & (US$ Million) Table 106. North America Oral Thrombopoietin Receptor Agonists Revenue by Country (2027-2032) & (US$ Million) Table 107. Europe Oral Thrombopoietin Receptor Agonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. Europe Oral Thrombopoietin Receptor Agonists Sales by Country (2021-2026) & (K Units) Table 109. Europe Oral Thrombopoietin Receptor Agonists Sales by Country (2027-2032) & (K Units) Table 110. Europe Oral Thrombopoietin Receptor Agonists Revenue by Country (2021-2026) & (US$ Million) Table 111. Europe Oral Thrombopoietin Receptor Agonists Revenue by Country (2027-2032) & (US$ Million) Table 112. Asia Pacific Oral Thrombopoietin Receptor Agonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Asia Pacific Oral Thrombopoietin Receptor Agonists Sales by Country (2021-2026) & (K Units) Table 114. Asia Pacific Oral Thrombopoietin Receptor Agonists Sales by Country (2027-2032) & (K Units) Table 115. Asia Pacific Oral Thrombopoietin Receptor Agonists Revenue by Country (2021-2026) & (US$ Million) Table 116. Asia Pacific Oral Thrombopoietin Receptor Agonists Revenue by Country (2027-2032) & (US$ Million) Table 117. South America Oral Thrombopoietin Receptor Agonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. South America Oral Thrombopoietin Receptor Agonists Sales by Country (2021-2026) & (K Units) Table 119. South America Oral Thrombopoietin Receptor Agonists Sales by Country (2027-2032) & (K Units) Table 120. South America Oral Thrombopoietin Receptor Agonists Revenue by Country (2021-2026) & (US$ Million) Table 121. South America Oral Thrombopoietin Receptor Agonists Revenue by Country (2027-2032) & (US$ Million) Table 122. Middle East and Africa Oral Thrombopoietin Receptor Agonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Middle East and Africa Oral Thrombopoietin Receptor Agonists Sales by Country (2021-2026) & (K Units) Table 124. Middle East and Africa Oral Thrombopoietin Receptor Agonists Sales by Country (2027-2032) & (K Units) Table 125. Middle East and Africa Oral Thrombopoietin Receptor Agonists Revenue by Country (2021-2026) & (US$ Million) Table 126. Middle East and Africa Oral Thrombopoietin Receptor Agonists Revenue by Country (2027-2032) & (US$ Million) Table 127. Global Oral Thrombopoietin Receptor Agonists Sales by Type (2021-2026) & (K Units) Table 128. Global Oral Thrombopoietin Receptor Agonists Sales by Type (2027-2032) & (K Units) Table 129. Global Oral Thrombopoietin Receptor Agonists Sales Market Share by Type (2021-2026) Table 130. Global Oral Thrombopoietin Receptor Agonists Sales Market Share by Type (2027-2032) Table 131. Global Oral Thrombopoietin Receptor Agonists Revenue by Type (2021-2026) & (US$ Million) Table 132. Global Oral Thrombopoietin Receptor Agonists Revenue by Type (2027-2032) & (US$ Million) Table 133. Global Oral Thrombopoietin Receptor Agonists Revenue Market Share by Type (2021-2026) Table 134. Global Oral Thrombopoietin Receptor Agonists Revenue Market Share by Type (2027-2032) Table 135. Global Oral Thrombopoietin Receptor Agonists Price by Type (2021-2026) & (US$/Unit) Table 136. Global Oral Thrombopoietin Receptor Agonists Price by Type (2027-2032) & (US$/Unit) Table 137. Global Oral Thrombopoietin Receptor Agonists Sales by Application (2021-2026) & (K Units) Table 138. Global Oral Thrombopoietin Receptor Agonists Sales by Application (2027-2032) & (K Units) Table 139. Global Oral Thrombopoietin Receptor Agonists Sales Market Share by Application (2021-2026) Table 140. Global Oral Thrombopoietin Receptor Agonists Sales Market Share by Application (2027-2032) Table 141. Global Oral Thrombopoietin Receptor Agonists Revenue by Application (2021-2026) & (US$ Million) Table 142. Global Oral Thrombopoietin Receptor Agonists Revenue by Application (2027-2032) & (US$ Million) Table 143. Global Oral Thrombopoietin Receptor Agonists Revenue Market Share by Application (2021-2026) Table 144. Global Oral Thrombopoietin Receptor Agonists Revenue Market Share by Application (2027-2032) Table 145. Global Oral Thrombopoietin Receptor Agonists Price by Application (2021-2026) & (US$/Unit) Table 146. Global Oral Thrombopoietin Receptor Agonists Price by Application (2027-2032) & (US$/Unit) Table 147. Key Raw Materials Table 148. Raw Materials Key Suppliers Table 149. Oral Thrombopoietin Receptor Agonists Distributors List Table 150. Oral Thrombopoietin Receptor Agonists Customers List Table 151. Oral Thrombopoietin Receptor Agonists Industry Trends Table 152. Oral Thrombopoietin Receptor Agonists Industry Drivers Table 153. Oral Thrombopoietin Receptor Agonists Industry Restraints Table 154. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Oral Thrombopoietin Receptor Agonists Product Image Figure 5. Global Oral Thrombopoietin Receptor Agonists Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Oral Thrombopoietin Receptor Agonists Market Size (2021-2032) & (US$ Million) Figure 7. Global Oral Thrombopoietin Receptor Agonists Sales (2021-2032) & (K Units) Figure 8. Global Oral Thrombopoietin Receptor Agonists Average Price (US$/Unit) & (2021-2032) Figure 9. Avatrombopag Product Image Figure 10. Eltrombopag Product Image Figure 11. Herombopag Product Image Figure 12. Lusutrombopag Product Image Figure 13. Hospital and Clinic Product Image Figure 14. Pharmacy Product Image Figure 15. Other Product Image Figure 16. Global Oral Thrombopoietin Receptor Agonists Revenue Share by Manufacturers in 2025 Figure 17. Global Manufacturers of Oral Thrombopoietin Receptor Agonists, Manufacturing Sites & Headquarters Figure 18. Global Top 5 and 10 Oral Thrombopoietin Receptor Agonists Players Market Share by Revenue in 2025 Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Oral Thrombopoietin Receptor Agonists Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 21. Global Oral Thrombopoietin Receptor Agonists Sales by Region in 2025 Figure 22. Global Oral Thrombopoietin Receptor Agonists Revenue by Region in 2025 Figure 23. North America Oral Thrombopoietin Receptor Agonists Market Size by Country in 2025 Figure 24. North America Oral Thrombopoietin Receptor Agonists Sales Market Share by Country (2021-2032) Figure 25. North America Oral Thrombopoietin Receptor Agonists Revenue Market Share by Country (2021-2032) Figure 26. United States Oral Thrombopoietin Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Canada Oral Thrombopoietin Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Mexico Oral Thrombopoietin Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Europe Oral Thrombopoietin Receptor Agonists Market Size by Country in 2025 Figure 30. Europe Oral Thrombopoietin Receptor Agonists Sales Market Share by Country (2021-2032) Figure 31. Europe Oral Thrombopoietin Receptor Agonists Revenue Market Share by Country (2021-2032) Figure 32. Germany Oral Thrombopoietin Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. France Oral Thrombopoietin Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. U.K. Oral Thrombopoietin Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Italy Oral Thrombopoietin Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Russia Oral Thrombopoietin Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Spain Oral Thrombopoietin Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Netherlands Oral Thrombopoietin Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Switzerland Oral Thrombopoietin Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Sweden Oral Thrombopoietin Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Poland Oral Thrombopoietin Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Asia Pacific Oral Thrombopoietin Receptor Agonists Market Size by Country in 2025 Figure 43. Asia Pacific Oral Thrombopoietin Receptor Agonists Sales Market Share by Country (2021-2032) Figure 44. Asia Pacific Oral Thrombopoietin Receptor Agonists Revenue Market Share by Country (2021-2032) Figure 45. China Oral Thrombopoietin Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Japan Oral Thrombopoietin Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. South Korea Oral Thrombopoietin Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. India Oral Thrombopoietin Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Australia Oral Thrombopoietin Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Taiwan Oral Thrombopoietin Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Southeast Asia Oral Thrombopoietin Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Oral Thrombopoietin Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. South America Oral Thrombopoietin Receptor Agonists Market Size by Country in 2025 Figure 54. South America Oral Thrombopoietin Receptor Agonists Sales Market Share by Country (2021-2032) Figure 55. South America Oral Thrombopoietin Receptor Agonists Revenue Market Share by Country (2021-2032) Figure 56. Brazil Oral Thrombopoietin Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Argentina Oral Thrombopoietin Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Chile Oral Thrombopoietin Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Middle East and Africa Oral Thrombopoietin Receptor Agonists Market Size by Country in 2025 Figure 60. Middle East and Africa Oral Thrombopoietin Receptor Agonists Sales Market Share by Country (2021-2032) Figure 61. Middle East and Africa Oral Thrombopoietin Receptor Agonists Revenue Market Share by Country (2021-2032) Figure 62. Egypt Oral Thrombopoietin Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. South Africa Oral Thrombopoietin Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Israel Oral Thrombopoietin Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Türkiye Oral Thrombopoietin Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. GCC Countries Oral Thrombopoietin Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Global Oral Thrombopoietin Receptor Agonists Sales Market Share by Type (2021-2032) Figure 68. Global Oral Thrombopoietin Receptor Agonists Revenue Market Share by Type (2021-2032) Figure 69. Global Oral Thrombopoietin Receptor Agonists Price (US$/Unit) by Type (2021-2032) Figure 70. Global Oral Thrombopoietin Receptor Agonists Sales Market Share by Application (2021-2032) Figure 71. Global Oral Thrombopoietin Receptor Agonists Revenue Market Share by Application (2021-2032) Figure 72. Global Oral Thrombopoietin Receptor Agonists Price (US$/Unit) by Application (2021-2032) Figure 73. Oral Thrombopoietin Receptor Agonists Value Chain Figure 74. Oral Thrombopoietin Receptor Agonists Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Oral Thrombopoietin Receptor Agonists Industry Opportunities and Challenges

Scope & coverage.

Types
  • Avatrombopag
  • Eltrombopag
  • Herombopag
  • Lusutrombopag
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • Chia Tai Tianqing Pharmaceutical
  • Grand Pharmaceutical
  • Sichuan Kelun Pharmaceutical
  • 3SBio
  • Qilu Pharmaceutical
  • Jiangsu Hengrui Pharmaceuticals
  • Shanghai Fosun Pharmaceutical
  • Teva
  • Shionogi
  • Novartis
  • Hetero
  • Annora Pharma
  • Amneal Pharmaceuticals
  • AkaRx
  • Actavis Laboratories

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Oral Thrombopoietin Receptor Agonists Market Size (2021-2032)
  4. 2.2.2 Global Oral Thrombopoietin Receptor Agonists Sales (2021-2032)
  5. 2.2.3 Global Oral Thrombopoietin Receptor Agonists Market Average Price (2021-2032)
  6. 2.3 Oral Thrombopoietin Receptor Agonists by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Avatrombopag
  9. 2.3.3 Eltrombopag
  10. 2.3.4 Herombopag
  11. 2.3.5 Lusutrombopag
  12. 2.4 Oral Thrombopoietin Receptor Agonists by Application
  13. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  14. 2.4.2 Hospital and Clinic
  15. 2.4.3 Pharmacy
  16. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Oral Thrombopoietin Receptor Agonists Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Oral Thrombopoietin Receptor Agonists Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Oral Thrombopoietin Receptor Agonists Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Oral Thrombopoietin Receptor Agonists Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Oral Thrombopoietin Receptor Agonists Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Oral Thrombopoietin Receptor Agonists, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Oral Thrombopoietin Receptor Agonists, Product Type & Application
  8. 3.8 Global Manufacturers of Oral Thrombopoietin Receptor Agonists, Established Date
  9. 3.9 Global Oral Thrombopoietin Receptor Agonists Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Chia Tai Tianqing Pharmaceutical
  2. 4.1.1 Chia Tai Tianqing Pharmaceutical Company Information
  3. 4.1.2 Chia Tai Tianqing Pharmaceutical Business Overview
  4. 4.1.3 Chia Tai Tianqing Pharmaceutical Oral Thrombopoietin Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Chia Tai Tianqing Pharmaceutical Oral Thrombopoietin Receptor Agonists Product Portfolio
  6. 4.1.5 Chia Tai Tianqing Pharmaceutical Recent Developments
  7. 4.2 Grand Pharmaceutical
  8. 4.2.1 Grand Pharmaceutical Company Information
  9. 4.2.2 Grand Pharmaceutical Business Overview
  10. 4.2.3 Grand Pharmaceutical Oral Thrombopoietin Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Grand Pharmaceutical Oral Thrombopoietin Receptor Agonists Product Portfolio
  12. 4.2.5 Grand Pharmaceutical Recent Developments
  13. 4.3 Sichuan Kelun Pharmaceutical
  14. 4.3.1 Sichuan Kelun Pharmaceutical Company Information
  15. 4.3.2 Sichuan Kelun Pharmaceutical Business Overview
  16. 4.3.3 Sichuan Kelun Pharmaceutical Oral Thrombopoietin Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Sichuan Kelun Pharmaceutical Oral Thrombopoietin Receptor Agonists Product Portfolio
  18. 4.3.5 Sichuan Kelun Pharmaceutical Recent Developments
  19. 4.4 3SBio
  20. 4.4.1 3SBio Company Information
  21. 4.4.2 3SBio Business Overview
  22. 4.4.3 3SBio Oral Thrombopoietin Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 3SBio Oral Thrombopoietin Receptor Agonists Product Portfolio
  24. 4.4.5 3SBio Recent Developments
  25. 4.5 Qilu Pharmaceutical
  26. 4.5.1 Qilu Pharmaceutical Company Information
  27. 4.5.2 Qilu Pharmaceutical Business Overview
  28. 4.5.3 Qilu Pharmaceutical Oral Thrombopoietin Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Qilu Pharmaceutical Oral Thrombopoietin Receptor Agonists Product Portfolio
  30. 4.5.5 Qilu Pharmaceutical Recent Developments
  31. 4.6 Jiangsu Hengrui Pharmaceuticals
  32. 4.6.1 Jiangsu Hengrui Pharmaceuticals Company Information
  33. 4.6.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  34. 4.6.3 Jiangsu Hengrui Pharmaceuticals Oral Thrombopoietin Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Jiangsu Hengrui Pharmaceuticals Oral Thrombopoietin Receptor Agonists Product Portfolio
  36. 4.6.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  37. 4.7 Shanghai Fosun Pharmaceutical
  38. 4.7.1 Shanghai Fosun Pharmaceutical Company Information
  39. 4.7.2 Shanghai Fosun Pharmaceutical Business Overview
  40. 4.7.3 Shanghai Fosun Pharmaceutical Oral Thrombopoietin Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Shanghai Fosun Pharmaceutical Oral Thrombopoietin Receptor Agonists Product Portfolio
  42. 4.7.5 Shanghai Fosun Pharmaceutical Recent Developments
  43. 4.8 Teva
  44. 4.8.1 Teva Company Information
  45. 4.8.2 Teva Business Overview
  46. 4.8.3 Teva Oral Thrombopoietin Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Teva Oral Thrombopoietin Receptor Agonists Product Portfolio
  48. 4.8.5 Teva Recent Developments
  49. 4.9 Shionogi
  50. 4.9.1 Shionogi Company Information
  51. 4.9.2 Shionogi Business Overview
  52. 4.9.3 Shionogi Oral Thrombopoietin Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Shionogi Oral Thrombopoietin Receptor Agonists Product Portfolio
  54. 4.9.5 Shionogi Recent Developments
  55. 4.10 Novartis
  56. 4.10.1 Novartis Company Information
  57. 4.10.2 Novartis Business Overview
  58. 4.10.3 Novartis Oral Thrombopoietin Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Novartis Oral Thrombopoietin Receptor Agonists Product Portfolio
  60. 4.10.5 Novartis Recent Developments
  61. 4.11 Hetero
  62. 4.11.1 Hetero Company Information
  63. 4.11.2 Hetero Business Overview
  64. 4.11.3 Hetero Oral Thrombopoietin Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Hetero Oral Thrombopoietin Receptor Agonists Product Portfolio
  66. 4.11.5 Hetero Recent Developments
  67. 4.12 Annora Pharma
  68. 4.12.1 Annora Pharma Company Information
  69. 4.12.2 Annora Pharma Business Overview
  70. 4.12.3 Annora Pharma Oral Thrombopoietin Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Annora Pharma Oral Thrombopoietin Receptor Agonists Product Portfolio
  72. 4.12.5 Annora Pharma Recent Developments
  73. 4.13 Amneal Pharmaceuticals
  74. 4.13.1 Amneal Pharmaceuticals Company Information
  75. 4.13.2 Amneal Pharmaceuticals Business Overview
  76. 4.13.3 Amneal Pharmaceuticals Oral Thrombopoietin Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Amneal Pharmaceuticals Oral Thrombopoietin Receptor Agonists Product Portfolio
  78. 4.13.5 Amneal Pharmaceuticals Recent Developments
  79. 4.14 AkaRx
  80. 4.14.1 AkaRx Company Information
  81. 4.14.2 AkaRx Business Overview
  82. 4.14.3 AkaRx Oral Thrombopoietin Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 AkaRx Oral Thrombopoietin Receptor Agonists Product Portfolio
  84. 4.14.5 AkaRx Recent Developments
  85. 4.15 Actavis Laboratories
  86. 4.15.1 Actavis Laboratories Company Information
  87. 4.15.2 Actavis Laboratories Business Overview
  88. 4.15.3 Actavis Laboratories Oral Thrombopoietin Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Actavis Laboratories Oral Thrombopoietin Receptor Agonists Product Portfolio
  90. 4.15.5 Actavis Laboratories Recent Developments
5 Global Oral Thrombopoietin Receptor Agonists Market Scenario by Region
  1. 5.1 Global Oral Thrombopoietin Receptor Agonists Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Oral Thrombopoietin Receptor Agonists Sales by Region: 2021-2032
  3. 5.2.1 Global Oral Thrombopoietin Receptor Agonists Sales by Region: 2021-2026
  4. 5.2.2 Global Oral Thrombopoietin Receptor Agonists Sales by Region: 2027-2032
  5. 5.3 Global Oral Thrombopoietin Receptor Agonists Revenue by Region: 2021-2032
  6. 5.3.1 Global Oral Thrombopoietin Receptor Agonists Revenue by Region: 2021-2026
  7. 5.3.2 Global Oral Thrombopoietin Receptor Agonists Revenue by Region: 2027-2032
  8. 5.4 North America Oral Thrombopoietin Receptor Agonists Market Facts & Figures by Country
  9. 5.4.1 North America Oral Thrombopoietin Receptor Agonists Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Oral Thrombopoietin Receptor Agonists Sales by Country (2021-2032)
  11. 5.4.3 North America Oral Thrombopoietin Receptor Agonists Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Oral Thrombopoietin Receptor Agonists Market Facts & Figures by Country
  16. 5.5.1 Europe Oral Thrombopoietin Receptor Agonists Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Oral Thrombopoietin Receptor Agonists Sales by Country (2021-2032)
  18. 5.5.3 Europe Oral Thrombopoietin Receptor Agonists Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Oral Thrombopoietin Receptor Agonists Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Oral Thrombopoietin Receptor Agonists Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Oral Thrombopoietin Receptor Agonists Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Oral Thrombopoietin Receptor Agonists Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Oral Thrombopoietin Receptor Agonists Market Facts & Figures by Country
  41. 5.7.1 South America Oral Thrombopoietin Receptor Agonists Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Oral Thrombopoietin Receptor Agonists Sales by Country (2021-2032)
  43. 5.7.3 South America Oral Thrombopoietin Receptor Agonists Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Oral Thrombopoietin Receptor Agonists Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Oral Thrombopoietin Receptor Agonists Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Oral Thrombopoietin Receptor Agonists Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Oral Thrombopoietin Receptor Agonists Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Oral Thrombopoietin Receptor Agonists Sales by Type (2021-2032)
  2. 6.1.1 Global Oral Thrombopoietin Receptor Agonists Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Oral Thrombopoietin Receptor Agonists Sales Market Share by Type (2021-2032)
  4. 6.2 Global Oral Thrombopoietin Receptor Agonists Revenue by Type (2021-2032)
  5. 6.2.1 Global Oral Thrombopoietin Receptor Agonists Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Oral Thrombopoietin Receptor Agonists Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Oral Thrombopoietin Receptor Agonists Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Oral Thrombopoietin Receptor Agonists Sales by Application (2021-2032)
  2. 7.1.1 Global Oral Thrombopoietin Receptor Agonists Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Oral Thrombopoietin Receptor Agonists Sales Market Share by Application (2021-2032)
  4. 7.2 Global Oral Thrombopoietin Receptor Agonists Revenue by Application (2021-2032)
  5. 7.2.1 Global Oral Thrombopoietin Receptor Agonists Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Oral Thrombopoietin Receptor Agonists Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Oral Thrombopoietin Receptor Agonists Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Oral Thrombopoietin Receptor Agonists Value Chain Analysis
  2. 8.1.1 Oral Thrombopoietin Receptor Agonists Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Oral Thrombopoietin Receptor Agonists Production Mode & Process
  5. 8.2 Oral Thrombopoietin Receptor Agonists Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Oral Thrombopoietin Receptor Agonists Distributors
  8. 8.2.3 Oral Thrombopoietin Receptor Agonists Customers
9 Global Oral Thrombopoietin Receptor Agonists Analyzing Market Dynamics
  1. 9.1 Oral Thrombopoietin Receptor Agonists Industry Trends
  2. 9.2 Oral Thrombopoietin Receptor Agonists Industry Drivers
  3. 9.3 Oral Thrombopoietin Receptor Agonists Industry Opportunities and Challenges
  4. 9.4 Oral Thrombopoietin Receptor Agonists Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.
      Talk to an analyst